Establishment of PANDA - a new human pancreatic ductal adenocarcinoma cell line with 3D cell culture technology

Romana Zahumenska, Michal Kalman, Juraj Marcinek, Sandra Mersakova, Martin Kertys, Miroslav Pindura, Blazej Palkoci, Roman Kycina, Martin Vojtko, Tomas Chromec, Hugo Dumortier, Henrieta Skovierova, Slavomira Novakova, Barbora Mitruskova, Ivan Kapralik, Dusan Loderer, Marian Grendar, Dusan Brany, Juraj Mokry, Michael Bouvet, Mark Valasek, Jan Janik, Lukas Plank, Ludovit Laca, Erika Halasova,  Jan Strnadel

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of malignancy with one of the worst prognoses amongst any type of cancer. Surgery is applicable only to the limited number of patients with locally resectable tumors and currently represents the only curative treatment option. Treatment with chemotherapy and radiotherapy can only extend patient survival. Despite advances in conventional therapies, the five-year survival of PDAC remained largely unchanged. New in vitro and in vivo models are therefore urgently needed to investigate this type of cancer. Here, we present the establishment and characterization of a novel pancreatic cancer cell line, isolated from a patient with PDAC. Cell line abbreviated as PANDA (PANncreatic Ductal Adenocarcinoma) was established with an optimized 3D culture protocol published previously by our group. The new cancer cell line “PANDA” represents a novel in vitro approach for PDAC cancer research and new therapy testing.